SCA
ABMD

Secor Capital Advisors’s Abiomed Inc ABMD Stock Holding History

Secor Capital Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,657
Closed -$3.54M – 604
2018
Q2 		$3.54M Buy
+8,657
New +$3.14M 0.3% 95

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Secor Capital Advisors's ABMD Position: Q3 2018 in Review

Secor Capital Advisors sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 8,657 shares — an estimated $3.54M sold.

Secor Capital Advisors first reported a position in ABMD in Q2 2018 and held it in 1 quarter. The position peaked at $3.54M in Q2 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

  • Secor Capital Advisors reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 8,657 Abiomed Inc shares in Q3 2018, an estimated $3.54M.
  • Secor Capital Advisors first reported a position in Abiomed Inc in Q2 2018 and held it in 1 quarter.
  • Secor Capital Advisors's Abiomed Inc position peaked at $3.54M in Q2 2018.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.